Navigation Links
Duke/Singapore scientists find new way to classify gastric cancers
Date:10/1/2009

DURHAM, N.C., -- An international team of scientists has discovered a new way to classify stomach cancers, and researchers say it may be an important step toward designing more effective treatments and improving long-term survival.

Stomach (gastric) cancer is particularly prevalent in Asia and represents the second leading cause of cancer deaths worldwide.

The research is based upon clinical findings from patients in Singapore, Australia and the United Kingdom and represents the largest genomic analysis of gastric cancers to date. The new system classifies gastric cancers by the signaling pathways the tumors use to grow and spread, as opposed to the more traditional approach that describes them by cell type or structure.

The findings, appearing online in the Public Library of Science journal PLoS Genetics, come from a group of scientists at the DukeNational University of Singapore Graduate Medical School in Singapore.

"We identified three oncogenic pathways that were activated in over 70 percent of the gastric tumors we examined," said lead author Chia Huey Ooi, PhD, Research Fellow in the Duke-NUS Graduate Medical School. "We also found that combinations of these pathways are significantly related to patient survival."

Stomach cancer is notoriously resistant to chemotherapy and newer biologic-based therapies have not proven very effective. With current treatments, less than a quarter of patients live longer than five years after surgery.

Study authors say the new classification system offers physicians the opportunity to stratify patients according to their tumors' pathway profiles and then apply the treatment that is designed to interrupt the signals those pathways use.

"These findings may give us the first way to truly offer our gastric cancer patients personalized medicine," says Patrick Tan, MD, PhD, the senior author of the study and a member of the Duke-NUS Graduate Medical School and the Genome Institute of Singapore.

Investigators obtained 301 gastric tumors from three independent patient groups. They used computational methods to map the activation levels of 11 different cell signaling pathways already known to be active in the development of gastric cancer. They found that three pathways primary drivers of cell growth and death (NF-kappaB, Wnt/β-catenin and proliferation/stem cell) were deregulated in most of the tumors.

The researchers found that stratifying patients by single pathways did not predict outcomes, but stratifying them by combinations of pathways did.

"We feel that the ability to perform 'high-throughput pathway profiling' opens up a number of interesting possibilities, says Tan, who is also a member of the Institute of Genome Sciences & Policy at Duke University Medical Center. "It suggests that pathway combinations, rather than single pathways alone, may play a more critical role in influencing tumor behavior. We feel our findings that the NF-kappaB pathway may be especially important, because this pathway has been understudied in gastric cancer. Finally, our methods could certainly be used to study pathway profiles in other cancers, which could lead to new insight into tumor behavior and outcomes."


'/>"/>

Contact: Michelle Gailiun
michelle.gailiun@duke.edu
919-660-1306
Duke University Medical Center
Source:Eurekalert

Related medicine news :

1. Scripps research scientists find missing puzzle piece of powerful DNA repair complex
2. Scientists decipher missing piece of first-responder DNA repair machine
3. University of Louisville neuroscientists hope to get people walking again
4. Oldest Skeleton in Human Family Tree Surprises Scientists
5. Scientists find obesity alone does not cause arthritis in animals
6. 2009 American Association of Pharmaceutical Scientists Annual Meeting and Exposition
7. Scientists Discover How Chemo Can Make Women Infertile
8. Scientists May Know How Lung Cancer Spreads
9. UCSF scientists illuminate how microRNAs drive tumor progression
10. Glaxo Official Memo Urged Scientists to Withhold Information About Paxils Risks, Trial Hears; Pharmaceutical Industry Today Offers Complete News Coverage
11. University of Hawaii at Manoa CRCH scientists report adulthood body size associated with cancer risk
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/9/2016)... Harrisburg, PA (PRWEB) , ... December 09, 2016 ... ... concussion education program through the Pennsylvania Cable Network (PCN) during the summer of ... Brain Injury Implementation Grant provided by the United States Department of Health and ...
(Date:12/8/2016)... Pennsylvania (PRWEB) , ... December 08, 2016 , ... ... Duck Donuts Franchising Company LLC, announced the first national #QuackGivesBack campaign which ... , “This was our first franchise-wide Quack Gives Back initiative, ...
(Date:12/8/2016)... , ... December 08, 2016 , ... CURE Media Group, ... and advocacy groups, has aligned with Upstage Lung Cancer in efforts to combat lung ... announcement, Michael J. Hennessy, Jr said, “CURE Media Group is honored to team up ...
(Date:12/8/2016)... ... December 08, 2016 , ... SunView Software aims ... employees that are both engaging and easy to use. Coming off the heels ... company revealed today its plans to roll out new AI-powered self-service enhancements to ...
(Date:12/8/2016)... Dallas, TX (PRWEB) , ... December 08, 2016 , ... ... to continue to be a convenient service for Texas, they are expanding their presence ... will involve a hiring spree that will bring new jobs to the Dallas and ...
Breaking Medicine News(10 mins):
(Date:12/9/2016)... 2016 Research and Markets has announced ... report to their offering. ... The report forecasts the global optical transceiver market to ... The report covers the present scenario and the growth ... the market size, the report considers the revenue generated from the ...
(Date:12/9/2016)... Pharma, Inc. (Nasdaq: LIFE ), a biotherapeutics company engaged ... rare diseases, today announced that senior management will participate in a ... at the InterContinental Barclay Hotel in New York City ... About aTyr Pharma ... aTyr Pharma is engaged in the discovery ...
(Date:12/9/2016)... 2016  Axovant Sciences Ltd. (NYSE: ... on the treatment of dementia, today announced a ... 2b trial evaluating treatment with intepirdine (RVT-101), combined ... plus placebo in people with mild-to-moderate Alzheimer,s disease. ... to treatment was associated with reduced progression in ...
Breaking Medicine Technology: